Testing selumetinib for adults and children with NF2-related schwannomatosis
Official title: Selumetinib for NF2-Related Schwannomatosis
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This trial is testing a drug called selumetinib in people with NF2-related schwannomatosis.
Read our full plain-language summary
What the trial team says
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.
Key facts
- Registry number
- NCT07707947
- Stage of testing
- Phase 2
- Conditions studied
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma, Ependymoma, Vestibular Schwannoma
Where it is running
This trial lists 1 site.
-
Beijing Municipality
- Beijing Tiantan Hospital, Capital Medical University (Beijing)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.